Bryan Ball Sells 6,596 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) insider Bryan Ball sold 6,596 shares of the business’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $3.43, for a total value of $22,624.28. Following the transaction, the insider owned 515,955 shares in the company, valued at approximately $1,769,725.65. This trade represents a 1.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.57, for a total value of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total value of $6,070.54.

Whitehawk Therapeutics Price Performance

Shares of WHWK stock opened at $4.00 on Wednesday. Whitehawk Therapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $4.48. The stock’s fifty day moving average price is $3.38 and its 200 day moving average price is $2.75. The company has a market cap of $188.80 million, a price-to-earnings ratio of 8.51 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Analysts Set New Price Targets

A number of brokerages have commented on WHWK. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. JonesTrading began coverage on Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Finally, Oppenheimer began coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target for the company. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.50.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of WHWK. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics in the 4th quarter valued at about $28,000. ABG Innovation Capital Partners III GP Ltd acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $51,000. Dimensional Fund Advisors LP acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $84,000. Squarepoint Ops LLC acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $159,000. Finally, Marshall Wace LLP acquired a new position in shares of Whitehawk Therapeutics in the 4th quarter valued at about $164,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.